Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-127031
Filing Date
2024-11-14
Accepted
2024-11-14 16:05:27
Documents
58
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q fbrx-20240930.htm   iXBRL 10-Q 1889465
2 EX-31.1 fbrx-ex31_1.htm EX-31.1 15993
3 EX-31.2 fbrx-ex31_2.htm EX-31.2 15710
4 EX-32.1 fbrx-ex32_1.htm EX-32.1 9151
5 EX-32.2 fbrx-ex32_2.htm EX-32.2 9192
  Complete submission text file 0000950170-24-127031.txt   7008678

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT fbrx-20240930.xsd EX-101.SCH 961767
61 EXTRACTED XBRL INSTANCE DOCUMENT fbrx-20240930_htm.xml XML 1094462
Mailing Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247
Business Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247 (310) 618-6994
Forte Biosciences, Inc. (Filer) CIK: 0001419041 (see all company filings)

EIN.: 261243872 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38052 | Film No.: 241461889
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)